Geron Corporation's ( NASDAQ:GERN ) blood disorder drug, Imetelstat, has received a crucial vote of confidence from advisers to the U.S. Food and Drug Administration (FDA). Despite initial concerns raised by the agency's staff regarding data clarity and safety issues, the advisory panel overwhelmingly backed the benefits of Imetelstat for treating...
Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 2.2/61.80%
Chart time frame : B
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress : B
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) Hit the bottom
D) Hit the top
Stocks rise as they rise from support and fall from resistance....
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue...
Shares of Geron have been on the retail trader’s radar following a series of news and industry catalysts. The late-stage biopharmaceutical company specializes in developing treatments for hematologic malignancies. At the beginning of the year, the company announced positive top-line results from its IMerge Phase 3 trials of imetelstat.
t’s the company’s candidate...
Setup: Rocketbase
VCP: 5W 39/6 4T
RS: 98
The posted chart contains a VCP (volatility contraction pattern). The first label "W" stands for weekly and shows the duration of the entire consolidation. In the middle label, the percentage of contractions is indicated (for example, "15/4"), with 15 representing the -15% depth of the base and 4 representing -4% of the...
NASDAQ:GERN
Chart showing good uptrend with average directional index
and sitting above the cloud,
GERN had a micro pullback on Friday and so is now
ready for an entry.
Resistance @ 3.20 back in 2019; Potential upside 35% or more.
$2.5 Strike Expiring 8/19.
B or X Wave. Recovery within a recovery.
This is a reflection using technical analysis + only and we do not consider valuation and macro factors at this stage.
The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels...
All, this chart sucks in all honestly, but think we are looking at a reversal here, needs to hold exact level it's at before moving up or may drop down one level bounce and should break out the top. Either way WW this week/next.
Support line
Entry 1.65
Stop 1.25
Target 3.3
I am not a PRO trader. I trade option to test my trading plan with small cost.
The max Risk of each plan is less than 1% of my account.
If you like this idea, please use SIM/Demo account to try it.
NASDAQ:GERN
Possible Scenario: LONG
Evidence: Price Action
This is my idea and could be wrong 100%
* It's a good buy opportunity right now, and it's ready to fly soon.
Bought this yesterday with the following reasons:
1. Stoch RSI at oversold level
2. Fibo and extended fibo retracement levels are followed
3. Realistic target prices
4. Tolerable cutloss level
Bought at 2, targetting 2.36 in two trading days! If it breaks 2.36 next week, I guess this stock will ride a rocket. Newbie trader here :)
